{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T01:54:50Z","timestamp":1789437290341,"version":"build-2803163510"},"reference-count":40,"publisher":"American Association of Psychiatric Pharmacists (AAPP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n        <jats:p>\n          <jats:bold>Introduction:<\/jats:bold> Antipsychotics represent a large portion of the psychotropics that may induce hyperprolactinemia. Clinical psychiatric pharmacists must be adept in stratifying the relative risk of hyperprolactinemia among psychotropics, identifying patient risk factors, recognizing differential diagnoses, and recommending therapeutic alternatives and treatment strategies. High-potency, typical antipsychotics are more likely to elevate prolactin although exceptions to the rule exist.<\/jats:p>\n        <jats:p>\n          <jats:bold>Methods:<\/jats:bold> A literature search of PubMed and Google Scholar was performed to identify English language articles on the treatment of antipsychotic-induced hyperprolactinemia in humans. Methodological rigor is summarized for compiled studies in addition to feasibility and limitations of application to clinical practice.<\/jats:p>\n        <jats:p>\n          <jats:bold>Results:<\/jats:bold> There is an absence of robust evidence for the management of antipsychotic-induced hyperprolactinemia. Among the pharmacological treatments studied, aripiprazole (switching or augmentation) possessed the strongest evidence. Pharmacological treatments with less evidence encompassed dose reduction, switching to lower potency antipsychotics, and adding dopamine agonists. To date, no head-to-head studies have been published on the above approaches.<\/jats:p>\n        <jats:p>\n          <jats:bold>Discussion:<\/jats:bold> Atypical antipsychotics with low affinity for dopamine (D2) receptors, such as olanzapine, are logical alternatives for the patient experiencing drug-induced hyperprolactinemia. When augmentation is clinically preferred to switching, a viable option is the addition of a full or partial dopamine agonist, such as bromocriptine or aripiprazole, respectively. Patient-specific risk of psychiatric decompensation and the severity of symptomatic hyperprolactinemia should be weighed when formulating treatment strategies.<\/jats:p>","DOI":"10.9740\/mhc.2016.07.185","type":"journal-article","created":{"date-parts":[[2016,6,29]],"date-time":"2016-06-29T21:29:33Z","timestamp":1467235773000},"page":"185-190","source":"Crossref","is-referenced-by-count":35,"title":["Management of antipsychotic-induced hyperprolactinemia"],"prefix":"10.9740","volume":"6","author":[{"given":"Ashley","family":"Tewksbury","sequence":"first","affiliation":[{"name":"(Corresponding author) Pharmacist, Clinical Specialist Psychiatry, Lutheran Hospital, Cleveland Clinic, Cleveland, Ohio, tewksba@ccf.org"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Olander","sequence":"additional","affiliation":[{"name":"PharmD Candidate, The Ohio State University College of Pharmacy, Columbus, Ohio"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4719","reference":[{"issue":"1","key":"i2168-9709-6-4-185-b01","series-title":"Psychosomatics","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.psym.2013.08.008","article-title":"Psychotropic-induced hyperprolactinemia: a clinical review","volume":"55","author":"Ajmal \n              A,","year":"2014","unstructured":"Ajmal \n              A, \n            \n            \n              Joffe \n              H, \n            \n            \n              Nachtigall \n              LB. \n            \n          \n          Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics. 2014;55(1):29-36. DOI: 10.1016\/j.psym.2013.08.008. PubMed PMID: 24140188."},{"issue":"11","key":"i2168-9709-6-4-185-b02","series-title":"J Clin Psychiatry","first-page":"1491","article-title":"Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment","volume":"65","author":"Montgomery \n              J,","year":"2004","unstructured":"Montgomery \n              J, \n            \n            \n              Winterbottom \n              E, \n            \n            \n              Jessani \n              M, \n            \n            \n              Kohegyi \n              E, \n            \n            \n              Fulmer \n              J, \n            \n            \n              Seamonds \n              B, \n            \n            et al. \n          Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65(11):1491-8. PubMed PMID: 15554761."},{"issue":"5","key":"i2168-9709-6-4-185-b03","series-title":"CNS Drugs","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40263-014-0157-3","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens \n              J,","year":"2014","unstructured":"Peuskens \n              J, \n            \n            \n              Pani \n              L, \n            \n            \n              Detraux \n              J, \n            \n            \n              De Hert \n              M. \n            \n          \n          The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs. 2014;28(5):421-53. DOI: 10.1007\/s40263-014-0157-3. PubMed PMID: 24677189."},{"issue":"1","key":"i2168-9709-6-4-185-b04","series-title":"Pharmacotherapy","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1592\/phco.29.1.64","article-title":"Antipsychotic-induced hyperprolactinemia","volume":"29","author":"Bostwick \n              JR,","year":"2009","unstructured":"Bostwick \n              JR, \n            \n            \n              Guthrie \n              SK, \n            \n            \n              Ellingrod \n              VL. \n            \n          \n          Antipsychotic-induced hyperprolactinemia. Pharmacotherapy. 2009;29(1):64-73. DOI: 10.1592\/phco.29.1.64. PubMed PMID: 19113797."},{"issue":"5","key":"i2168-9709-6-4-185-b05","series-title":"Pharmacogenet Genomics","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1097\/FPC.0b013e328329a60f","article-title":"Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents","volume":"19","author":"Calarge \n              CA,","year":"2009","unstructured":"Calarge \n              CA, \n            \n            \n              Ellingrod \n              VL, \n            \n            \n              Acion \n              L, \n            \n            \n              Miller \n              DD, \n            \n            \n              Moline \n              J, \n            \n            \n              Tansey \n              MJ, \n            \n            et al. \n          Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics. 2009;19(5):373-82. DOI: 10.1097\/FPC.0b013e328329a60f. PubMed PMID: 19339912."},{"issue":"20","key":"i2168-9709-6-4-185-b06","series-title":"Drugs","first-page":"2291","article-title":"Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management","volume":"64","author":"Haddad \n              PM,","year":"2004","unstructured":"Haddad \n              PM, \n            \n            \n              Wieck \n              A. \n            \n          \n          Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64(20):2291-314. PubMed PMID: 15456328."},{"issue":"3","key":"i2168-9709-6-4-185-b07","series-title":"Am J Psychiatry","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis","volume":"158","author":"Kapur \n              S,","year":"2001","unstructured":"Kapur \n              S, \n            \n            \n              Seeman \n              P. \n            \n          \n          Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry. 2001;158(3):360-9. DOI: 10.1176\/appi.ajp.158.3.360. PubMed PMID: 11229973."},{"issue":"2","key":"i2168-9709-6-4-185-b08","series-title":"J Clin Endocrinol Metab","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","article-title":"Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline","volume":"96","author":"Melmed \n              S,","year":"2011","unstructured":"Melmed \n              S, \n            \n            \n              Casanueva \n              FF, \n            \n            \n              Hoffman \n              AR, \n            \n            \n              Kleinberg \n              DL, \n            \n            \n              Montori \n              VM, \n            \n            \n              Schlechte \n              JA, \n            \n            et al. \n          Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(2):273-88. DOI: 10.1210\/jc.2010-1692. PubMed PMID: 21296991."},{"issue":"4","key":"i2168-9709-6-4-185-b09","series-title":"Hum Psychopharmacol","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/hup.1116","article-title":"Hyperprolactinemia associated with psychotropics\u2014a review","volume":"25","author":"Madhusoodanan \n              S,","year":"2010","unstructured":"Madhusoodanan \n              S, \n            \n            \n              Parida \n              S, \n            \n            \n              Jimenez \n              C. \n            \n          \n          Hyperprolactinemia associated with psychotropics\u2014a review. Hum Psychopharmacol. 2010;25(4):281-97. DOI: 10.1002\/hup.1116. PubMed PMID: 20521318."},{"issue":"12","key":"i2168-9709-6-4-185-b10","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e82749","DOI":"10.1371\/journal.pone.0082749","article-title":"Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study","volume":"8","author":"Kim \n              S,","year":"2013","unstructured":"Kim \n              S, \n            \n            \n              Park \n              YM. \n            \n          \n          Serum prolactin and macroprolactin levels among outpatients with major depressive disorder following the administration of selective serotonin-reuptake inhibitors: a cross-sectional pilot study. PLoS One. 2013;8(12):e82749. DOI: 10.1371\/journal.pone.0082749. PubMed PMID: 24312671."},{"issue":"1","key":"i2168-9709-6-4-185-b11","series-title":"BMC Psychiatry","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/1471-244X-13-214","article-title":"Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin)","volume":"13","author":"Kelly \n              DL,","year":"2013","unstructured":"Kelly \n              DL, \n            \n            \n              Wehring \n              HJ, \n            \n            \n              Earl \n              AK, \n            \n            \n              Sullivan \n              KM, \n            \n            \n              Dickerson \n              FB, \n            \n            \n              Feldman \n              S, \n            \n            et al. \n          Treating symptomatic hyperprolactinemia in women with schizophrenia: presentation of the ongoing DAAMSEL clinical trial (Dopamine partial Agonist, Aripiprazole, for the Management of Symptomatic ELevated prolactin). BMC Psychiatry. 2013;13(1):214. DOI: 10.1186\/1471-244X-13-214. PubMed PMID: 23968123."},{"issue":"5","key":"i2168-9709-6-4-185-b12","series-title":"Psychoneuroendocrinology","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.psyneuen.2005.12.006","article-title":"Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine","volume":"31","author":"Kinon \n              BJ,","year":"2006","unstructured":"Kinon \n              BJ, \n            \n            \n              Ahl \n              J, \n            \n            \n              Liu-Seifert \n              H, \n            \n            \n              Maguire \n              GA. \n            \n          \n          Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;31(5):577-88. DOI: 10.1016\/j.psyneuen.2005.12.006. PubMed PMID: 16488084."},{"issue":"8","key":"i2168-9709-6-4-185-b13","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1016\/j.pnpbp.2008.09.016","article-title":"Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole","volume":"32","author":"Lu \n              M-L,","year":"2008","unstructured":"Lu \n              M-L, \n            \n            \n              Shen \n              WW, \n            \n            \n              Chen \n              C-H. \n            \n          \n          Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(8):1978-81. DOI: 10.1016\/j.pnpbp.2008.09.016. PubMed PMID: 18848860."},{"issue":"5","key":"i2168-9709-6-4-185-b14","series-title":"J Clin Psychiatry","first-page":"408","article-title":"Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone","volume":"63","author":"Kim \n              K-S,","year":"2002","unstructured":"Kim \n              K-S, \n            \n            \n              Pae \n              C-U, \n            \n            \n              Chae \n              J-H, \n            \n            \n              Bahk \n              W-M, \n            \n            \n              Jun \n              T-Y, \n            \n            \n              Kim \n              D-J, \n            \n            et al. \n          Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J Clin Psychiatry. 2002;63(5):408-13. PubMed PMID: 12019665."},{"issue":"1","key":"i2168-9709-6-4-185-b15","series-title":"J Child Adolesc Psychopharmacol","first-page":"65","article-title":"Attenuation of antipsychotic-induced hyperprolactinemia with clozapine","volume":"7","author":"Bunker \n              MT,","year":"1997","unstructured":"Bunker \n              MT, \n            \n            \n              Marken \n              PA, \n            \n            \n              Schneiderhan \n              ME, \n            \n            \n              Ruehter \n              VL. \n            \n          \n          Attenuation of antipsychotic-induced hyperprolactinemia with clozapine. J Child Adolesc Psychopharmacol. 1997;7(1):65-9. PubMed PMID: 9192542."},{"issue":"10","key":"i2168-9709-6-4-185-b16","series-title":"Am J Psychiatry","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1176\/ajp.155.10.1458","article-title":"Olanzapine use in women with antipsychotic-induced hyperprolactinemia","volume":"155","author":"Canuso \n              CM,","year":"1998","unstructured":"Canuso \n              CM, \n            \n            \n              Hanau \n              M, \n            \n            \n              Jhamb \n              KK, \n            \n            \n              Green \n              AI. \n            \n          \n          Olanzapine use in women with antipsychotic-induced hyperprolactinemia. Am J Psychiatry. 1998;155(10):1458. DOI: 10.1176\/ajp.155.10.1458. PubMed PMID: 9766782."},{"key":"i2168-9709-6-4-185-b17","series-title":"Psychopharmacology (Berl)","first-page":"391","article-title":"Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study","volume":"166","author":"Casey \n              DE,","year":"2003","unstructured":"Casey \n              DE, \n            \n            \n              Caron \n              WH, \n            \n            \n              Saha \n              AR, \n            \n            \n              Liebeskind \n              A, \n            \n            \n              Ali \n              MW, \n            \n            \n              Jody \n              D, \n            \n            et al. \n          Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl). 2003;166:391-9. PubMed PMID: 12610718."},{"issue":"2-3","key":"i2168-9709-6-4-185-b18","series-title":"Schizophr Res","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.schres.2008.09.019","article-title":"Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study","volume":"107","author":"Byerly \n              MJ,","year":"2009","unstructured":"Byerly \n              MJ, \n            \n            \n              Marcus \n              RN, \n            \n            \n              Tran \n              Q-V, \n            \n            \n              Eudicone \n              JM, \n            \n            \n              Whitehead \n              R, \n            \n            \n              Baker \n              RA. \n            \n          \n          Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophr Res. 2009;107(2-3):218-22. DOI: 10.1016\/j.schres.2008.09.019. PubMed PMID: 19038534."},{"issue":"9","key":"i2168-9709-6-4-185-b19","series-title":"Am J Psychiatry","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1176\/appi.ajp.2007.06071075","article-title":"Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial","volume":"164","author":"Shim \n              J-C,","year":"2007","unstructured":"Shim \n              J-C, \n            \n            \n              Shin \n              J-GK, \n            \n            \n              Kelly \n              DL, \n            \n            \n              Jung \n              D-U, \n            \n            \n              Seo \n              Y-S, \n            \n            \n              Liu \n              K-H, \n            \n            et al. \n          Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry. 2007;164(9):1404-10. DOI: 10.1176\/appi.ajp.2007.06071075. PubMed PMID: 17728426."},{"issue":"5","key":"i2168-9709-6-4-185-b20","series-title":"J Clin Psychopharmacol","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1097\/JCP.0b013e3181ee832d","article-title":"Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia","volume":"30","author":"Yasui-Furukori \n              N,","year":"2010","unstructured":"Yasui-Furukori \n              N, \n            \n            \n              Furukori \n              H, \n            \n            \n              Sugawara \n              N, \n            \n            \n              Fujii \n              A, \n            \n            \n              Kaneko \n              S. \n            \n          \n          Dose-dependent effects of adjunctive treatment with aripiprazole on hyperprolactinemia induced by risperidone in female patients with schizophrenia. J Clin Psychopharmacol. 2010;30(5):596-9. DOI: 10.1097\/JCP.0b013e3181ee832d. PubMed PMID: 20814333."},{"issue":"8","key":"i2168-9709-6-4-185-b21","series-title":"Prog Neuropsychopharmacol Biol Psychiatry","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.pnpbp.2010.08.012","article-title":"Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics","volume":"34","author":"Chen \n              C-K,","year":"2010","unstructured":"Chen \n              C-K, \n            \n            \n              Huang \n              Y-S, \n            \n            \n              Ree \n              S-C, \n            \n            \n              Hsiao \n              C-C. \n            \n          \n          Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(8):1495-9. DOI: 10.1016\/j.pnpbp.2010.08.012. PubMed PMID: 20732372."},{"issue":"1","key":"i2168-9709-6-4-185-b22","series-title":"J Clin Psychopharmacol","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/JCP.0b013e318205e1aa","article-title":"Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection","volume":"31","author":"van Kooten \n              M,","year":"2011","unstructured":"van Kooten \n              M, \n            \n            \n              Arends \n              J, \n            \n            \n              Cohen \n              D. \n            \n          \n          Preliminary report: a naturalistic study of the effect of aripiprazole addition on risperidone-related hyperprolactinemia in patients treated with risperidone long-acting injection. J Clin Psychopharmacol. 2011;31(1):126-8. DOI: 10.1097\/JCP.0b013e318205e1aa. PubMed PMID: 21192158."},{"issue":"4","key":"i2168-9709-6-4-185-b23","series-title":"J Clin Psychopharmacol","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1097\/JCP.0b013e3182970431","article-title":"Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection","volume":"33","year":"2013","unstructured":"Ziadi Trives M, Bonete Ll\u00e1cer JM, Garc\u00eda Escudero MA, Mart\u00ednez Paster CJ. Effect of the addition of aripiprazole on hyperprolactinemia associated with risperidone long-acting injection. J Clin Psychopharmacol. 2013;33(4):538-41. DOI: 10.1097\/JCP.0b013e3182970431. PubMed PMID: 23775053."},{"issue":"8","key":"i2168-9709-6-4-185-b24","series-title":"PLoS One","doi-asserted-by":"publisher","first-page":"e70179","DOI":"10.1371\/journal.pone.0070179","article-title":"Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials","volume":"8","author":"Li \n              X,","year":"2013","unstructured":"Li \n              X, \n            \n            \n              Tang \n              Y, \n            \n            \n              Wang \n              C. \n            \n          \n          Adjunctive aripiprazole versus placebo for antipsychotic-induced hyperprolactinemia: meta-analysis of randomized controlled trials. PLoS One. 2013;8(8):e70179. DOI: 10.1371\/journal.pone.0070179. PubMed PMID: 23936389."},{"issue":"1","key":"i2168-9709-6-4-185-b25","series-title":"Shanghai Arch Psychiatry","doi-asserted-by":"publisher","first-page":"4","DOI":"10.11919\/j.issn.1002-0829.215014","article-title":"Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials","volume":"27","author":"Meng \n              M,","year":"2015","unstructured":"Meng \n              M, \n            \n            \n              Li \n              W, \n            \n            \n              Zhang \n              S, \n            \n            \n              Wang \n              H, \n            \n            \n              Sheng \n              J, \n            \n            \n              Wang \n              JJ, \n            \n            et al. \n          Using aripiprazole to reduce antipsychotic-induced hyperprolactinemia: meta-analysis of currently available randomized controlled trials. Shanghai Arch Psychiatry. 2015;27(1):4-17. DOI: 10.11919\/j.issn.1002-0829.215014. PubMed PMID: 25852251."},{"key":"i2168-9709-6-4-185-b26","series-title":"Prim Care Companion CNS Disord","doi-asserted-by":"publisher","DOI":"10.4088\/PCC.13l01519","article-title":"Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics","author":"Boggs \n              DL,","year":"2013","unstructured":"Boggs \n              DL, \n            \n            \n              Ranganathan \n              M, \n            \n            \n              Boggs \n              AA, \n            \n            \n              Bihday \n              CM, \n            \n            \n              Peluse \n              BE, \n            \n            \n              D'Souza \n              DC. \n            \n          \n          Treatment of hyperprolactinemia and gynecomastia with adjunctive aripiprazole in 2 men receiving long-acting injectable antipsychotics. Prim Care Companion CNS Disord. 2013;15(4):pii:PCC.13l01519.DOI: 10.4088\/PCC.13l01519. PubMed PMID: 24392257."},{"issue":"1","key":"i2168-9709-6-4-185-b27","series-title":"Int J Neuropsychopharmacol","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1017\/S1461145706007115","article-title":"Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole","volume":"10","author":"Paulzen \n              M,","year":"2007","unstructured":"Paulzen \n              M, \n            \n            \n              Gr\u00fcnder \n              G. \n            \n          \n          Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol. 2007;10(1):149-51. DOI: 10.1017\/S1461145706007115. PubMed PMID: 16942633."},{"issue":"1","key":"i2168-9709-6-4-185-b28","series-title":"Psychiatry Clin Neurosci","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/j.1440-1819.2009.02032.x","article-title":"Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study","volume":"64","author":"Lee \n              M-S,","year":"2010","unstructured":"Lee \n              M-S, \n            \n            \n              Song \n              H-C, \n            \n            \n              An \n              H, \n            \n            \n              Yang \n              J, \n            \n            \n              Ko \n              Y-H, \n            \n            \n              Jung \n              I-K, \n            \n            et al. \n          Effect of bromocriptine on antipsychotic drug-induced hyperprolactinemia: eight-week randomized, single-blind, placebo-controlled, multicenter study. Psychiatry Clin Neurosci. 2010;64(1):19-27. DOI: 10.1111\/j.1440-1819.2009.02032.x. PubMed PMID: 19968833."},{"issue":"2","key":"i2168-9709-6-4-185-b29","series-title":"J Clin Psychiatry","first-page":"187","article-title":"Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study","volume":"65","author":"Cavallaro \n              R,","year":"2004","unstructured":"Cavallaro \n              R, \n            \n            \n              Cocchi \n              F, \n            \n            \n              Angelone \n              SM, \n            \n            \n              Lattuada \n              E, \n            \n            \n              Smeraldi \n              E. \n            \n          \n          Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry. 2004;65(2):187-90. PubMed PMID: 15003071."},{"issue":"4","key":"i2168-9709-6-4-185-b30","series-title":"Exp Clin Psychopharmacol","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1037\/a0033448","article-title":"Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients","volume":"21","author":"Kalkavoura \n              CS,","year":"2013","unstructured":"Kalkavoura \n              CS, \n            \n            \n              Michopoulos \n              I, \n            \n            \n              Arvanitakis \n              P, \n            \n            \n              Theodoropoulou \n              P, \n            \n            \n              Dimopoulou \n              K, \n            \n            \n              Tzebelikos \n              E, \n            \n            et al. \n          Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients. Exp Clin Psychopharmacol. 2013;21(4):332-41. DOI: 10.1037\/a0033448. PubMed PMID: 23834553."},{"issue":"2","key":"i2168-9709-6-4-185-b31","series-title":"J Clin Psychiatry","doi-asserted-by":"publisher","first-page":"269","DOI":"10.4088\/JCP.v66n0217e","article-title":"Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine","volume":"66","author":"Miller \n              DE,","year":"2005","unstructured":"Miller \n              DE, \n            \n            \n              Sebastian \n              CS. \n            \n          \n          Olanzapine-induced hyperprolactinemia and galactorrhea reversed with addition of bromocriptine. J Clin Psychiatry. 2005;66(2):269-70. DOI: 10.4088\/JCP.v66n0217e. PubMed PMID: 15705020."},{"issue":"2","key":"i2168-9709-6-4-185-b32","series-title":"J Clin Psychopharmacol","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1097\/JCP.0b013e31820f4fbd","article-title":"Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia","volume":"31","author":"Ishitobi \n              M,","year":"2011","unstructured":"Ishitobi \n              M, \n            \n            \n              Kosaka \n              H, \n            \n            \n              Shukunami \n              K, \n            \n            \n              Murata \n              T, \n            \n            \n              Wada \n              Y. \n            \n          \n          Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia. J Clin Psychopharmacol. 2011;31(2):243-45. DOI: 10.1097\/JCP.0b013e31820f4fbd. PubMed PMID: 21364336."},{"issue":"4","key":"i2168-9709-6-4-185-b33","series-title":"Pharmacopsychiatry","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1055\/s-2004-827176","article-title":"Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report","volume":"37","author":"Bliesener \n              N,","year":"2004","unstructured":"Bliesener \n              N, \n            \n            \n              Yokusoglu \n              H, \n            \n            \n              Quednow \n              BB, \n            \n            \n              Klingm\u00fcller \n              D, \n            \n            \n              K\u00fchn \n              KU. \n            \n          \n          Usefulness of bromocriptine in the treatment of amisulpride-induced hyperprolactinemia: a case report. Pharmacopsychiatry. 2004;37(4):189-91. DOI: 10.1055\/s-2004-827176. PubMed PMID: 15467977."},{"issue":"11","key":"i2168-9709-6-4-185-b34","series-title":"J Endocrinol Invest","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/BF03345068","article-title":"Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders","volume":"23","author":"Tollin \n              SR.","year":"2000","unstructured":"Tollin \n              SR. \n            \n          \n          Use of the dopamine agonists bromocriptine and cabergoline in the management of risperidone-induced hyperprolactinemia in patients with psychotic disorders. J Endocrinol Invest. 2000;23(11):765-70. DOI: 10.1007\/BF03345068. PubMed PMID: 11194712."},{"issue":"2","key":"i2168-9709-6-4-185-b35","series-title":"Curr Drug Saf","first-page":"92","article-title":"Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics","volume":"7","author":"Coronas \n              R,","year":"2012","unstructured":"Coronas \n              R, \n            \n            \n              Cobo \n              J, \n            \n            \n              Gim\u00e9nez-Palop \n              O, \n            \n            \n              Ortega \n              E, \n            \n            \n              M\u00e1rquez \n              M. \n            \n          \n          Safety of cabergoline in the management of pituitary prolactin-induced symptoms with patients treated with atypical neuroleptics. Curr Drug Saf. 2012;7(2):92-8. PubMed PMID: 22873493."},{"issue":"4","key":"i2168-9709-6-4-185-b36","series-title":"J Child Adolesc Psychopharmacol","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1089\/104454601317261618","article-title":"Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children","volume":"11","author":"Cohen \n              LG,","year":"2001","unstructured":"Cohen \n              LG, \n            \n            \n              Biederman \n              J. \n            \n          \n          Treatment of risperidone-induced hyperprolactinemia with a dopamine agonist in children. J Child Adolesc Psychopharmacol. 2001;11(4):435-40. DOI: 10.1089\/104454601317261618. PubMed PMID: 11838826."},{"issue":"4-5","key":"i2168-9709-6-4-185-b37","series-title":"Acta Obstet Gynecol Scand","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3109\/00016349109007893","article-title":"Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia","volume":"70","author":"Dorevitch \n              A,","year":"1991","unstructured":"Dorevitch \n              A, \n            \n            \n              Aronzon \n              R, \n            \n            \n              Stark \n              M. \n            \n          \n          Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia. Acta Obstet Gynecol Scand. 1991;70(4-5):375-76. DOI: 10.3109\/00016349109007893. PubMed PMID: 1746267."},{"key":"i2168-9709-6-4-185-b38","series-title":"Psychoneuroendocrinology","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.psyneuen.2015.04.011","article-title":"Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study","volume":"58","author":"Chen \n              J-X,","year":"2015","unstructured":"Chen \n              J-X, \n            \n            \n              Su \n              Y-A, \n            \n            \n              Bian \n              Q-T, \n            \n            \n              Wei \n              L-H, \n            \n            \n              Zhang \n              R-Z, \n            \n            \n              Liu \n              Y-H, \n            \n            et al. \n          Adjunctive aripiprazole in the treatment of risperidone-induced hyperprolactinemia: A randomized, double-blind, placebo-controlled, dose-response study. Psychoneuroendocrinology. 2015;58:130-40. DOI: 10.1016\/j.psyneuen.2015.04.011. PubMed PMID: 25981348."},{"issue":"1","key":"i2168-9709-6-4-185-b39","series-title":"Int J Neuropsychopharmacol","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1017\/S1461145706006523","article-title":"Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole","volume":"10","author":"Raja \n              M.","year":"2007","unstructured":"Raja \n              M. \n            \n          \n          Improvement or worsening of psychotic symptoms after treatment with low doses of aripiprazole. Int J Neuropsychopharmacol. 2007;10(1):107-10. DOI: 10.1017\/S1461145706006523. PubMed PMID: 16487453."},{"issue":"2","key":"i2168-9709-6-4-185-b40","series-title":"Int J Psychiatry Clin Pract","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3109\/13651501.2011.644300","article-title":"Severe psychotic exacerbation during combined treatment with aripiprazole\/haloperidol after prior treatment with risperidone","volume":"16","author":"Letmaier \n              M,","year":"2012","unstructured":"Letmaier \n              M, \n            \n            \n              Painold \n              A, \n            \n            \n              Holl \n              AK, \n            \n            \n              Grohmann \n              R, \n            \n            \n              Vergin \n              H. \n            \n          \n          Severe psychotic exacerbation during combined treatment with aripiprazole\/haloperidol after prior treatment with risperidone. Int J Psychiatry Clin Pract. 2012;16(2):153-6. DOI: 10.3109\/13651501.2011.644300. PubMed PMID: 22211772."}],"container-title":["Mental Health Clinician"],"original-title":[],"link":[{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/6\/4\/article-p185.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/mhc\/article-pdf\/6\/4\/185\/2095445\/mhc_2016_07_185.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/6\/4\/article-p185.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/mhc.kglmeridian.com\/downloadpdf\/journals\/mhcl\/6\/4\/article-p185.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,20]],"date-time":"2024-11-20T00:36:29Z","timestamp":1732062989000},"score":1,"resource":{"primary":{"URL":"https:\/\/mhc.kglmeridian.com\/view\/journals\/mhcl\/6\/4\/article-p185.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":40,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.9740\/mhc.2016.07.185","relation":{},"ISSN":["2168-9709"],"issn-type":[{"value":"2168-9709","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}